Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 250
Filter
1.
PLoS One ; 12(7): e0180778, 2017.
Article in English | MEDLINE | ID: mdl-28686637

ABSTRACT

African Americans have higher rates of asthma prevalence, morbidity, and mortality in comparison with other racial groups. We sought to characterize endotypes of childhood asthma severity in African American patients in an inner-city pediatric asthma population. Baseline blood neutrophils, blood eosinophils, and 38 serum cytokine levels were measured in a sample of 235 asthmatic children (6-17 years) enrolled in the NIAID (National Institute of Allergy and Infectious Diseases)-sponsored Asthma Phenotypes in the Inner City (APIC) study (ICAC (Inner City Asthma Consortium)-19). Cytokines were quantified using a MILLIPLEX panel and analyzed on a Luminex analyzer. Patients were classified as Easy-to-Control or Difficult-to-Control based on the required dose of controller medications over one year of prospective management. A multivariate variable selection procedure was used to select cytokines associated with Difficult-to-Control versus Easy-to-Control asthma, adjusting for age, sex, blood eosinophils, and blood neutrophils. In inner-city African American children, 12 cytokines were significant predictors of Difficult-to-Control asthma (n = 235). CXCL-1, IL-5, IL-8, and IL-17A were positively associated with Difficult-to-Control asthma, while IL-4 and IL-13 were positively associated with Easy-to-Control asthma. Using likelihood ratio testing, it was observed that in addition to blood eosinophils and neutrophils, serum cytokines improved the fit of the model. In an inner-city pediatric population, serum cytokines significantly contributed to the definition of Difficult-to-Control asthma endotypes in African American children. Mixed responses characterized by TH2 (IL-5) and TH17-associated cytokines were associated with Difficult-to-Control asthma. Collectively, these data may contribute to risk stratification of Difficult-to-Control asthma in the African American population.


Subject(s)
Anti-Asthmatic Agents/administration & dosage , Asthma/blood , Asthma/drug therapy , Cytokines/blood , Adolescent , Black or African American , Asthma/pathology , Blood Cell Count , Child , Eosinophils/pathology , Female , Humans , Male , Neutrophils/pathology
2.
Allergy ; 70(10): 1309-18, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26119467

ABSTRACT

BACKGROUND: Genome-wide association studies (GWASs) have identified various genes associated with asthma, yet, causal genes or single nucleotide polymorphisms (SNPs) remain elusive. We sought to dissect functional genes/SNPs for asthma by combining expression quantitative trait loci (eQTLs) and GWASs. METHODS: Cis-eQTL analyses of 34 asthma genes were performed in cells from human bronchial epithelial biopsy (BEC, n = 107) and from bronchial alveolar lavage (BAL, n = 94). RESULTS: For TSLP-WDR36 region, rs3806932 (G allele protective against eosinophilic esophagitis) and rs2416257 (A allele associated with lower eosinophil counts and protective against asthma) were correlated with decreased expression of TSLP in BAL (P = 7.9 × 10(-11) and 5.4 × 10(-4) , respectively) and BEC, but not WDR36. Surprisingly, rs1837253 (consistently associated with asthma) showed no correlation with TSLP expression levels. For ORMDL3-GSDMB region, rs8067378 (G allele protective against asthma) was correlated with decreased expression of GSDMB in BEC and BAL (P = 1.3 × 10(-4) and 0.04) but not ORMDL3. rs992969 in the promoter region of IL33 (A allele associated with higher eosinophil counts and risk for asthma) was correlated with increased expression of IL33 in BEC (P = 1.3 × 10(-6) ) but not in BAL. CONCLUSIONS: Our study illustrates cell-type-specific regulation of the expression of asthma-related genes documenting SNPs in TSLP, GSDMB, IL33, HLA-DQB1, C11orf30, DEXI, CDHR3, and ZBTB10 affect asthma risk through cis-regulation of its gene expression. Whenever possible, disease-relevant tissues should be used for transcription analysis. SNPs in TSLP may affect asthma risk through up-regulating TSLP mRNA expression or protein secretion. Further functional studies are warranted.


Subject(s)
Asthma/genetics , Bronchoalveolar Lavage Fluid , Epithelial Cells/metabolism , Genetic Predisposition to Disease , Genome-Wide Association Study , Quantitative Trait Loci , Respiratory Mucosa/metabolism , Alleles , Asthma/immunology , Asthma/physiopathology , Bronchoalveolar Lavage Fluid/cytology , Bronchoalveolar Lavage Fluid/immunology , Case-Control Studies , Chromosome Mapping , Female , Genetic Association Studies , Humans , Immunoglobulin E/immunology , Male , Organ Specificity/genetics , Polymorphism, Single Nucleotide , Respiratory Function Tests
3.
Allergy ; 69(11): 1522-30, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25040613

ABSTRACT

BACKGROUND: Inhaled glucocorticosteroids (ICS) are the mainstay of treatment in asthma. Fluticasone furoate (FF) is a novel, once-daily ICS asthma therapy. This study investigated the efficacy and safety of FF 50 mcg in patients with mild-to-moderate persistent asthma. METHODS: A 24-week, multicenter, randomized, placebo-controlled and active-controlled, double-blind, double-dummy, parallel-group phase III study. Three hundred and fifty-one patients (aged ≥12 years; uncontrolled by non-ICS therapy) were randomized to treatment (1 : 1 : 1) with once-daily FF 50 mcg dosed in the evening, twice-daily fluticasone propionate (FP) 100 mcg or placebo. The primary endpoint was change from baseline in evening trough forced expiratory volume in 1 s (FEV1 ) at Week 24. Secondary endpoints were change from baseline in the percentage of rescue-free 24-h periods (powered endpoint), change from baseline in evening and morning peak expiratory flow, change from baseline in the percentage of symptom-free 24-h periods and number of withdrawals due to lack of efficacy. RESULTS: Evening trough FEV1 at Week 24 was not statistically significantly increased with FF 50 mcg once-daily (37 ml [95% CI: -55, 128]; P = 0.430), but was with FP 100 mcg twice daily (102 ml [10, 194]; P = 0.030), vs placebo. No consistent trends were observed across other endpoints, including the powered secondary endpoint. No safety concerns were raised for either active treatment. CONCLUSIONS: FP 100 mcg twice daily improved evening trough FEV1 in patients with mild-to-moderate persistent asthma, but FF 50 mcg once daily did not demonstrate a significant effect. Secondary endpoints showed variable results. No safety concerns were identified for FF or FP.


Subject(s)
Androstadienes/administration & dosage , Anti-Asthmatic Agents/administration & dosage , Asthma/drug therapy , Adolescent , Adult , Androstadienes/adverse effects , Anti-Asthmatic Agents/adverse effects , Asthma/diagnosis , Drug Administration Schedule , Female , Forced Expiratory Volume , Humans , Male , Middle Aged , Severity of Illness Index , Treatment Outcome , Young Adult
4.
Mucosal Immunol ; 7(5): 1175-85, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24518246

ABSTRACT

Severe refractory asthma is associated with enhanced nitrative stress. To determine the mechanisms for high nitrative stress in human severe asthma (SA), 3-nitrotyrosine (3NT) was compared with Th1 and Th2 cytokine expression. In SA, high 3NT levels were associated with high interferon (IFN)-γ and low interleukin (IL)-13 expression, both of which have been reported to increase inducible nitric oxide synthase (iNOS) in human airway epithelial cells (HAECs). We found that IL-13 and IFN-γ synergistically enhanced iNOS, nitrite, and 3NT, corresponding with increased H(2)O(2). Catalase inhibited whereas superoxide dismutase enhanced 3NT formation, supporting a critical role for H(2)O(2), but not peroxynitrite, in 3NT generation. Dual oxidase-2 (DUOX2), central to H(2)O(2) formation, was also synergistically induced by IL-13 and IFN-γ. The catalysis of nitrite and H(2)O(2) to nitrogen dioxide radical (NO(2)(•)) requires an endogenous peroxidase in this epithelial cell system. Thyroid peroxidase (TPO) was identified by microarray analysis ex vivo as a gene distinguishing HAEC of SA from controls. IFN-γ induced TPO in HAEC and small interfering RNA knockdown decreased nitrated tyrosine residues. Ex vivo, DUOX2, TPO, and iNOS were higher in SA and correlated with 3NT. Thus, a novel iNOS-DUOX2-TPO-NO(2)(•) metabolome drives nitrative stress in HAEC and likely in SA.


Subject(s)
Asthma/enzymology , Asthma/physiopathology , Metabolome , Nitric Oxide Synthase Type II/immunology , Stress, Physiological , Th1 Cells/immunology , Th2 Cells/immunology , Adult , Asthma/immunology , Female , Humans , Interferon-gamma/pharmacology , Interleukin-13/pharmacology , Iodide Peroxidase/metabolism , Male , Microarray Analysis , Respiratory System/enzymology , Respiratory System/physiopathology , Severity of Illness Index , Stress, Physiological/drug effects , Th1 Cells/drug effects , Th2 Cells/drug effects , Young Adult
5.
Int Arch Allergy Immunol ; 158(3): 216-31, 2012.
Article in English | MEDLINE | ID: mdl-22382913

ABSTRACT

Concepts of disease severity, activity, control and responsiveness to treatment are linked but different. Severity refers to the loss of function of the organs induced by the disease process or to the occurrence of severe acute exacerbations. Severity may vary over time and needs regular follow-up. Control is the degree to which therapy goals are currently met. These concepts have evolved over time for asthma in guidelines, task forces or consensus meetings. The aim of this paper is to generalize the approach of the uniform definition of severe asthma presented to WHO for chronic allergic and associated diseases (rhinitis, chronic rhinosinusitis, chronic urticaria and atopic dermatitis) in order to have a uniform definition of severity, control and risk, usable in most situations. It is based on the appropriate diagnosis, availability and accessibility of treatments, treatment responsiveness and associated factors such as comorbidities and risk factors. This uniform definition will allow a better definition of the phenotypes of severe allergic (and related) diseases for clinical practice, research (including epidemiology), public health purposes, education and the discovery of novel therapies.


Subject(s)
Asthma/physiopathology , Hypersensitivity/complications , Practice Guidelines as Topic/standards , Severity of Illness Index , Asthma/therapy , Chronic Disease , Comorbidity , Dermatitis, Atopic/complications , Humans , Hypersensitivity/epidemiology , Rhinitis/complications , Rhinitis/epidemiology , Sinusitis/complications , Sinusitis/epidemiology , Urticaria/complications , Urticaria/epidemiology
6.
Respir Med ; 104(2): 188-96, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19846286

ABSTRACT

Eosinophilia is an established marker of asthma-related inflammation. We assessed the effect of omalizumab on peripheral blood eosinophil counts using a pooled analysis of data from five randomized, double-blind, placebo-controlled studies in patients with moderate-to-severe persistent allergic asthma receiving moderate-to-high-dose inhaled corticosteroids (omalizumab, n=1136; placebo, n=1100). Relationships between omalizumab, peripheral blood eosinophils, serum free IgE concentrations and clinical outcomes were explored. Baseline mean eosinophil counts were similar in each treatment group. Post-treatment eosinophil counts were significantly reduced from baseline in the omalizumab group (p<0.0001) but were not significantly different in the placebo group. Greater reductions in eosinophil counts were observed in patients who had post-treatment free IgE levels <50ng/mL. Three studies included steroid-stable and steroid-reduction phases. At the end of each phase in these studies, a significantly greater reduction in eosinophil counts was achieved in the omalizumab group compared with the placebo group (p<0.0001). A consistent pattern of improved clinical outcomes/decreased eosinophils and worsened clinical outcomes/increased eosinophils was observed for both omalizumab and placebo treatment groups. The findings from our analysis of a large patient population are consistent with earlier reports of the inhibitory effect of omalizumab on eosinophils.


Subject(s)
Anti-Asthmatic Agents/pharmacology , Asthma/complications , Eosinophilia/drug therapy , Eosinophils/drug effects , Immunoglobulin E/blood , Adolescent , Adult , Aged , Antibodies, Anti-Idiotypic , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal, Humanized , Asthma/blood , Asthma/drug therapy , Child , Dose-Response Relationship, Drug , Eosinophilia/blood , Eosinophils/metabolism , Female , Humans , Immunoglobulin E/drug effects , Inflammation/blood , Inflammation/drug therapy , Male , Middle Aged , Omalizumab , Randomized Controlled Trials as Topic , Treatment Outcome , Young Adult
7.
Clin Exp Allergy ; 39(9): 1324-9, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19638039

ABSTRACT

Rackemann described the 'intrinsic asthma' population over 50 years ago as a unique subgroup that was characterized by onset of progressive loss of lung function beginning later in life, possibly after a respiratory infection. It has also been associated with a female predominance, aspirin-sensitive bronchospasm, and nasal polyposis. While the aetiology is not understood, we propose that persistent respiratory infections play a central role in the development of intrinsic asthma.


Subject(s)
Asthma/etiology , Respiratory Tract Infections/complications , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Aspirin/adverse effects , Aspirin/therapeutic use , Asthma/immunology , Asthma/physiopathology , Bronchial Spasm/etiology , Bronchial Spasm/immunology , Bronchial Spasm/physiopathology , Female , Humans , Lung/immunology , Lung/physiopathology , Male , Nasal Polyps/complications , Nasal Polyps/immunology , Nasal Polyps/physiopathology , Respiratory Tract Infections/immunology , Respiratory Tract Infections/physiopathology , Sex Factors
8.
Eur Respir J ; 32(3): 545-54, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18757695

ABSTRACT

Concepts of asthma severity and control are important in the evaluation of patients and their response to treatment but the terminology is not standardised and the terms are often used interchangeably. This review, arising from the work of an American Thoracic Society/European Respiratory Society Task Force, identifies the need for separate concepts of control and severity, describes their evolution in asthma guidelines and provides a framework for understanding the relationship between current concepts of asthma phenotype, severity and control. "Asthma control" refers to the extent to which the manifestations of asthma have been reduced or removed by treatment. Its assessment should incorporate the dual components of current clinical control (e.g. symptoms, reliever use and lung function) and future risk (e.g. exacerbations and lung function decline). The most clinically useful concept of asthma severity is based on the intensity of treatment required to achieve good asthma control, i.e. severity is assessed during treatment. Severe asthma is defined as the requirement for (not necessarily just prescription or use of) high-intensity treatment. Asthma severity may be influenced by the underlying disease activity and by the patient's phenotype, both of which may be further described using pathological and physiological markers. These markers can also act as surrogate measures for future risk.


Subject(s)
Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Asthma/physiopathology , Practice Guidelines as Topic , Clinical Trials as Topic , Drug Resistance , Humans , Respiratory Function Tests
9.
Allergy ; 63(7): 932-8, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18588561

ABSTRACT

BACKGROUND: Uncontrolled asthma is characterized by variability. Current asthma guidelines recommend focussing on the achievement and maintenance of control but few studies have examined in detail, using composite measures of control, the stability and potential duration of control once achieved. In this post-hoc analysis of the results of the Gaining Optimal Asthma controL (GOAL) study, we examine the association between the level of asthma control achieved during the step-up phase of the study and the stability of control experienced during the maintenance phase. METHODS: GOAL was a 1-year, randomized, stratified, double-blind study of 3421 patients with uncontrolled asthma, which compared salmeterol/fluticasone propionate combination with fluticasone propionate in achieving two composite, guideline-based measures of control: totally controlled and well-controlled asthma. We analysed the proportion and duration of time spent in control, the effect of treatment on asthma stability, and the impact of asthma control stability on unscheduled use of healthcare resources. RESULTS: In patients achieving well-controlled or totally controlled asthma, at least well-controlled asthma was maintained for a median of almost 3 and 6 months, and for more than 85% and 95% of weeks of follow-up, respectively. A high level of stability was confirmed in a Markov analysis investigating transitional probability of change in control status. Variability in control was associated with increased probability of an unscheduled healthcare resource use (odds ratio: 1.06, P < 0.001). CONCLUSIONS: Most patients achieving guideline-defined control can maintain at least a similar level of control with regular, stable dosing, with little likelihood of losing control.


Subject(s)
Albuterol/analogs & derivatives , Androstadienes/therapeutic use , Asthma/drug therapy , Bronchodilator Agents/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Albuterol/therapeutic use , Child , Double-Blind Method , Drug Combinations , Fluticasone , Fluticasone-Salmeterol Drug Combination , Humans , Logistic Models , Markov Chains , Middle Aged , Odds Ratio , Time Factors
10.
Clin Pharmacol Ther ; 83(2): 307-11, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17625517

ABSTRACT

The suitability of employing AIR Inhaled Insulin (AIR Insulin; AIR is a registered trademark of Alkermes) during acute upper respiratory tract infection (URI) has not been determined. Twenty-one healthy, non-diabetic subjects were enrolled in a single-sequence, two-period, euglycemic clamp study. Subjects received a single 12 U-equivalent dose of AIR Insulin before rhinovirus (RV16) inoculation and during symptomatic infection. Spirometry was used to evaluate pulmonary safety. AIR Insulin exposure (the area under the immunoreactive insulin (IRI) concentration vs time curve from time zero until the IRI concentrations returned to the predose baseline value (AUC(0-t'))) and glucodynamic response (total amount of glucose infused (G(tot))) were comparable before and during RV infection (AUC(0-t') 46,300 vs 52,600 pmol min/l, P=0.21; G(tot) 61,800 vs 68,700 mg, P=0.42, respectively). Variability of pharmacokinetic and pharmacodynamic parameters did not change during URI; either did the number or intensity of adverse events. No significant change in forced expiratory volume or forced vital capacity was observed following AIR Insulin administration or during URI. The AIR Insulin system provides similar pharmacokinetic and glucodynamic responses under conditions of an experimentally induced RV infection and is regarded as suitable for use in diabetic patients during URIs.


Subject(s)
Blood Glucose/drug effects , Hypoglycemic Agents/pharmacokinetics , Insulin/pharmacokinetics , Picornaviridae Infections/metabolism , Respiratory Tract Infections/metabolism , Administration, Oral , Adult , Area Under Curve , Forced Expiratory Volume , Glucose Clamp Technique , Humans , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/adverse effects , Insulin/administration & dosage , Insulin/adverse effects , Picornaviridae Infections/physiopathology , Respiratory Tract Infections/physiopathology , Respiratory Tract Infections/virology , Spirometry , Vital Capacity
11.
Eur Respir J ; 29(1): 56-62, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17050557

ABSTRACT

The present study examined the association between guideline-derived asthma control and health-related quality of life, assessed using the Asthma Quality of Life Questionnaire (AQLQ), in patients with uncontrolled asthma whose treatment was directed towards achieving the highest possible level of control. The present randomised, double-blind, parallel-group study compared the efficacy of fluticasone propionate (FP) and salmeterol/fluticasone propionate combination (SFC) in achieving two composite, guideline-derived measures of control: total control (TC) and well-controlled (WC) asthma. Not achieving these levels was classed as not well-controlled (NWC). Doses were augmented until patients achieved TC or reached the maximum dose. This dose was maintained for the remainder of the study. AQLQ was assessed at baseline and at each clinic visit. AQLQ scores improved throughout the study, reaching near-maximal levels in patients achieving TC and WC, and 52-week mean scores in the three control groups were statistically significantly different. Clinically meaningful improvements (mean change from baseline) were: TC group (SFC 1.9, FP 1.8), WC (SFC 1.5, FP 1.5) and NWC (SFC 1.0, FP 0.9). In conclusion, the treatment aimed at controlling asthma improves the health-related quality of life to levels approaching normal. The difference in Asthma Quality of Life Questionnaire scores between total control and well-controlled confirms that patients distinguish even between these high levels of control.


Subject(s)
Albuterol/analogs & derivatives , Androstadienes/administration & dosage , Asthma/drug therapy , Health Status , Quality of Life , Administration, Inhalation , Adolescent , Adult , Albuterol/administration & dosage , Bronchodilator Agents , Double-Blind Method , Drug Combinations , Female , Fluticasone , Fluticasone-Salmeterol Drug Combination , Humans , Male , Metered Dose Inhalers , Middle Aged , Treatment Outcome
12.
Thorax ; 61(9): 809-16, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16936237

ABSTRACT

The natural history of asthma involves relatively stable periods that are often punctuated by significant exacerbations of symptoms. There are many aetiologies that may lead to an increase in asthma severity including respiratory infection (bacterial/viral), allergens, irritants, and occupational exposures. Each trigger probably acts through different mechanisms, but a final common pathway of multicellular inflammation, enhanced bronchial responsiveness, and airflow obstruction is a likely consequence. This review discusses the most common causes of asthma exacerbations with a focus on their microbiology and immunopathogenesis. Through an understanding of underlying causes of asthma exacerbations, treatments with increased effectiveness may be developed, and it is these future developments that may directly influence the morbidity and mortality of the disease.


Subject(s)
Asthma/etiology , Influenza, Human/complications , Occupational Diseases/etiology , Picornaviridae Infections/complications , Asthma/immunology , Humans , Picornaviridae Infections/microbiology
13.
Allergy ; 61(5): 531-6, 2006 May.
Article in English | MEDLINE | ID: mdl-16629780

ABSTRACT

BACKGROUND: The Gaining Optimal Asthma ControL (GOAL) study has shown the superiority of a combination of salmeterol/fluticasone propionate (SFC) compared with fluticasone propionate alone (FP) in terms of improving guideline defined asthma control. METHODS: Clinical and economic data were taken from the GOAL study, supplemented with data on health related quality of life, in order to estimate the cost per quality adjusted life year (QALY) results for each of three strata (previously corticosteroid-free, low- and moderate-dose corticosteroid users). A series of statistical models of trial outcomes was used to construct cost effectiveness estimates across the strata of the multinational GOAL study including adjustment to the UK experience. Uncertainty was handled using the non-parametric bootstrap. Cost-effectiveness was compared with other treatments for chronic conditions. RESULT: Salmeterol/fluticasone propionate improved the proportion of patients achieving totally and well-controlled weeks resulting in a similar QALY gain across the three strata of GOAL. Additional costs of treatment were greatest in stratum 1 and least in stratum 3, with some of the costs offset by reduced health care resource use. Cost-effectiveness by stratum was 7600 pound (95% CI: 4800-10,700 pound) per QALY gained for stratum 3; 11,000 pound (8600-14,600 pound) per QALY gained for stratum 2; and 13,700 pound (11,000-18,300 pound) per QALY gained for stratum 1. CONCLUSION: The GOAL study previously demonstrated the improvement in total control associated with the use of SFC compared with FP alone. This study suggests that this improvement in control is associated with cost-per-QALY figures that compare favourably with other uses of scarce health care resources.


Subject(s)
Asthma/drug therapy , Asthma/economics , Bronchodilator Agents/economics , Outcome Assessment, Health Care/economics , Quality-Adjusted Life Years , Albuterol/analogs & derivatives , Albuterol/economics , Albuterol/therapeutic use , Androstadienes/economics , Androstadienes/therapeutic use , Bronchodilator Agents/therapeutic use , Cost-Benefit Analysis/methods , Cost-Benefit Analysis/statistics & numerical data , Double-Blind Method , Drug Combinations , Fluticasone , Fluticasone-Salmeterol Drug Combination , Humans , Models, Statistical , Outcome Assessment, Health Care/methods , Quality of Life , Time Factors , Treatment Outcome , United Kingdom
14.
Allergy ; 61(5): 589-97, 2006 May.
Article in English | MEDLINE | ID: mdl-16629789

ABSTRACT

BACKGROUND: The effector function of eosinophils involves their release of toxic granule proteins, reactive oxygen species, cytokines, and lipid mediators. Murine studies have demonstrated that eosinophils can also enhance T cell function. Whether human eosinophils, in particular, airway eosinophils, have similar immunoregulatory activity has not been fully investigated. The aim of this study was to determine whether human blood and airway eosinophils can contribute to Th1 and Th2 cytokine generation from CD4+ T cells stimulated with superantigen. METHODS: Eosinophils were obtained from blood or bronchoalveolar lavage fluid 48 h after segmental allergen bronchoprovocation. Purified eosinophils were co-cultured with autologous CD4+ blood T cells in the presence of staphylococcal enterotoxin B (SEB). Cytokine levels in the supernatant fluid were determined by enzyme-linked immunosorbent assay (ELISA). Eosinophil expression of major histocompatibility complex (MHC) class II and co-stimulatory molecules was assessed by flow cytometry before culture, 24 h after granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulation, and 24 h after co-culture with CD4+ T cells and SEB. RESULTS: Interleukin (IL)-5, IL-13, and interferon (IFN)-gamma generation increased when CD4+ T cells were co-cultured with either blood or airway eosinophils in the presence of SEB. The ability of eosinophils to enhance cytokine generation was independent of their source (blood vs airway), activation by GM-CSF, or detectable expression of human leukocyte antigen (HLA)-DR, CD80, or CD86. CONCLUSION: Our data demonstrate that SEB-induced generation of Th1 and Th2 cytokines is increased in the presence of human blood and airway eosinophils. Thus, eosinophils can have an immunoregulatory function in pathogen-associated allergic diseases such as atopic dermatitis, chronic sinusitis, and asthma exacerbations.


Subject(s)
Bronchoalveolar Lavage Fluid , Cytokines/metabolism , Eosinophils/physiology , Th1 Cells/metabolism , Th2 Cells/metabolism , Blood Cells/physiology , CD4-Positive T-Lymphocytes/metabolism , Cells, Cultured , Enterotoxins/metabolism , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Granulocyte-Macrophage Colony-Stimulating Factor/metabolism , Humans , In Vitro Techniques , Interferons/metabolism , Interleukin-5/metabolism , Th1 Cells/immunology , Th2 Cells/immunology
15.
Eur Respir J ; 24(4): 568-74, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15459134

ABSTRACT

Early intervention with budesonide is an effective strategy for mild persistent asthma, which has been shown to provide additional clinical benefits at a low incremental cost using USA cost data. The present authors analysed whether this strategy would be cost-effective using cost data for other countries. Based on the 3-yr prospective, randomised, double-blind inhaled Steroid Treatment As Regular Therapy (START) in early asthma study (comparing budesonide and placebo combined with usual asthma therapy), the cost-effectiveness was estimated separately for eight different countries, from both healthcare payer and societal perspectives, of adding budesonide to usual asthma therapy. Local unit costs were applied to data for the total trial population. Incremental cost-effectiveness ratios (ICER) were estimated as cost per symptom-free day (SFD) gained. Budesonide increased SFDs by an average of 14.1 days annually. From a healthcare payer perspective, budesonide would reduce the total cost of asthma care in Australia. In Sweden, Canada, France, Spain, UK, China and the USA, the ICER ranged from US$2.4-11.3 per SFD. From a societal perspective, budesonide would be cost-saving in Australia, Canada and Sweden. In conclusion, for countries where costs with budesonide are higher, the policy implication has to be determined by that health system's willingness to pay for an additional symptom-free day. However, where budesonide therapy increases symptom-free days and reduces total costs, the policy conclusion clearly favours early intervention.


Subject(s)
Asthma/economics , Bronchodilator Agents/economics , Budesonide/economics , Administration, Inhalation , Adolescent , Adult , Aged , Asthma/drug therapy , Australia , Bronchodilator Agents/administration & dosage , Budesonide/administration & dosage , Child , Child, Preschool , China , Cost-Benefit Analysis , Double-Blind Method , Europe , Female , Humans , Male , Middle Aged , North America , Prospective Studies
16.
Clin Exp Allergy ; 34(6): 897-903, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15196277

ABSTRACT

BACKGROUND: Allergic rhinitis and asthma often co-exist and appear to produce a continuum of airway disease, but whether the clinical characteristics of asthma in patients with seasonal rhinitis differ from those of persistent asthma has not been examined. OBJECTIVE: The aim of this retrospective study was to characterize the clinical features of patients with seasonal allergic rhinitis with concomitant asthma and to compare them with those in patients with persistent asthma. METHODS: The patient populations for this study were derived from nine prospective, placebo-controlled planned clinical trials of similar design. Six studies (958 patients) enrolled patients with seasonal allergic rhinitis and concomitant asthma; three (607 patients) involved patients with persistent asthma. In all studies, patients were excluded from oral corticosteroid therapy in the preceding 3 months, and from inhaled corticosteroids in the preceding month. RESULTS: Patients with seasonal rhinitis and asthma had a significantly (P<0.001) higher total asthma symptom score than those with persistent asthma. In particular, cough was three times more severe. The need for beta(2)-agonist as a rescue medication and the ratio of forced expiratory volume in 1 s/forced vital capacity (FVC) were similar in the two groups whereas forced expiratory fraction 25-75%/FVC was significantly (P<0.02) reduced in the persistent asthmatics. Asthma and nasal symptom severity scores were correlated in patients with seasonal rhinitis and asthma (P<0.0001). CONCLUSIONS: Patients with seasonal allergic rhinitis and concomitant asthma appear to differ from those with persistent asthma. A prospective study should be designed to discover whether patients with seasonal rhinitis and asthma may represent a distinct nosological entity, 'allergic airway disease'.


Subject(s)
Asthma/complications , Rhinitis, Allergic, Seasonal/complications , Adrenergic beta-Agonists/therapeutic use , Adult , Asthma/drug therapy , Asthma/physiopathology , Cough/complications , Cough/drug therapy , Female , Forced Expiratory Volume , Humans , Male , Respiratory Function Tests , Retrospective Studies , Rhinitis, Allergic, Seasonal/drug therapy , Rhinitis, Allergic, Seasonal/physiopathology , Statistics, Nonparametric
18.
Clin Exp Allergy ; 32(9): 1355-9, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12220475

ABSTRACT

BACKGROUND: Eosinophilic inflammation is a feature of asthma. However, serological markers to indicate eosinophil activation in this process are not fully defined. OBJECTIVE: To evaluate the relationship of serum eosinophil cationic protein (ECP) to asthma worsening and a marker for treatment effectiveness, 26 adult patients with an asthma exacerbation were identified. METHODS: Identified asthma subjects were treated with oral corticosteroids (prednisone) for 14 days. The lung function variables, forced expiratory volume in one second (FEV1) and peak expiratory flow (PEF), were determined as percentage of predicted and the blood total eosinophil count and serum ECP levels were measured. Patients were re-evaluated after 14 days of corticosteroid treatment and then every 3 months thereafter during a 12-month period. RESULTS: Eighteen patients responded to prednisone treatment, whereas eight did not, assessed as improvement of their lung function parameters. Different serum ECP patterns could be seen in the responders compared with the non-responders. All 18 responders had considerably increased serum ECP at the time of exacerbation, whereas the non-responders had lower serum ECP levels. The serum ECP levels decreased to a greater extent in the responder patient group than in the non-responder patients following prednisone treatment. This difference in patterns was not seen with total blood eosinophil counts. CONCLUSION: Our findings suggest that serum ECP may be used to predict a response to corticosteroid therapy in adult patients with asthma.


Subject(s)
Asthma/immunology , Blood Proteins/analysis , Ribonucleases , Acute Disease , Adolescent , Adult , Aged , Asthma/drug therapy , Asthma/physiopathology , Biomarkers/blood , Eosinophil Granule Proteins , Female , Forced Expiratory Volume , Glucocorticoids/therapeutic use , Humans , Inflammation , Lung/immunology , Lung/physiopathology , Male , Middle Aged , Peak Expiratory Flow Rate , Prednisone/therapeutic use , Prognosis , Prospective Studies , Treatment Outcome
19.
Respir Med ; 96(5): 293-304, 2002 May.
Article in English | MEDLINE | ID: mdl-12113378

ABSTRACT

Many companies are now prioritizing the development of dry powder inhalers (DPIs) above pressurized formulations of asthma drugs. A well-designed DPI and an appropriate powder formulation can optimize the effectiveness of inhaled drug therapy. A DPI must be able to deliver medications effectively for most patients, and an ideal inhaler would provide a dose that does not vary with inspiratory flow rate. Recent regulatory guidelines, among which the U.S. FDA draft guidance is the most stringent, demand consistent dose delivery from an inhaler throughout its life and consistency of doses from one inhaler to another. However, the properties of free micronized powders often interfere with drug handling and with drug delivery reducing dose consistency. Recent advances in formulation technology can increase lung dose and reduce its variability. While a perfect DPI may never exist, both device and formulation technology are evolving to rectify perceived deficiencies in earlier systems.


Subject(s)
Anti-Asthmatic Agents/administration & dosage , Asthma/drug therapy , Nebulizers and Vaporizers , Anti-Asthmatic Agents/chemistry , Chemistry, Pharmaceutical , Equipment Design , Humans
20.
Am J Respir Crit Care Med ; 164(8 Pt 2): S12-7, 2001 Oct 15.
Article in English | MEDLINE | ID: mdl-11704612

ABSTRACT

Several large-scale, double-blind, randomized, placebo-controlled clinical trials of the anti-immunoglobulin E (IgE) monoclonal antibody, rhuMAb-E25 (omalizumab) have demonstrated the benefits of this agent in patients with moderate to severe allergic asthma who remain symptomatic despite treatment with systemic or inhaled corticosteroids. The trials have consistently shown that administration of omalizumab is associated with fewer asthma exacerbations per patient despite significant reductions in corticosteroid dose, stable symptom control despite concomitant reductions in rescue medication use, and improvement in quality of life compared with placebo. In addition, anti-IgE (omalizumab) has been shown to be safe and well tolerated.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Asthma/therapy , Immunoglobulin E/immunology , Clinical Trials as Topic , Humans , Quality of Life
SELECTION OF CITATIONS
SEARCH DETAIL
...